August 3, 2017

Recurring Leukaemia Cells there from the Start

Analysing cancer stem cell populations in first-time patients enabled researchers to predict who was most likely to suffer a relapse. For some cancers, remission does not last long: The cancer...

eastRead More

Weizmann scientist at core of breakthrough blood cancer therapy

The breakthrough cancer therapy, currently making headlines for a United States study of leukaemia patients, has its origins at the Weizmann Institute of Science, Israel. Using genetically modified T-cells from…

eastRead More